 |
Eric J. Small, MD
Recent Publications |
Publications – 2008 |
 |
D'Amico, A.V., S. Halabi, R. Vollmer,
M. Loffredo, E. McMahon, B. Sanford, L. Archer, N.J. Vogelzang,
E.J. Small, and P.W. Kantoff, p53 Protein Expression Status
and Recurrence in Men Treated with Radiation and Androgen
Suppression Therapy for Higher-Risk Prostate Cancer: A Prospective
Phase II Cancer and Leukemia Group B Study (CALGB 9682).
Urology, 2008. |
|
Philips, G.K., S. Halabi, B.L. Sanford, D. Bajorin, and
E.J. Small, A phase II trial of cisplatin, fixed dose-rate
gemcitabine and gefitinib for advanced urothelial tract carcinoma:
results of the Cancer and Leukaemia Group B 90102. BJU Int,
2008. 101(1): p. 20-5. |
|
Rosenberg, J.E., S. Halabi, B.L. Sanford, A.L. Himelstein,
J.N. Atkins, R.J. Hohl, F. Millard, D.F. Bajorin, and E.J.
Small, Phase II study of bortezomib in patients with previously
treated advanced urothelial tract transitional cell carcinoma:
CALGB 90207. Ann Oncol, 2008. |
|
Ryan, C.J., A.H. Harzstark, J. Rosenberg, A. Lin, C. Claros,
I.D. Goldfine, J.F. Kerner, and E.J. Small, A pilot dose-escalation
study of the effects of nordihydroguareacetic acid on hormone
and prostate specific antigen levels in patients with relapsed
prostate cancer. BJU Int, 2008. 101(4): p. 436-9. |
|
Scher, H.I., S. Halabi, I. Tannock, M. Morris, C.N. Sternberg,
M.A. Carducci, M.A. Eisenberger, C. Higano, G.J. Bubley,
R. Dreicer, D. Petrylak, P. Kantoff, E. Basch, W.K. Kelly,
W.D. Figg, E.J. Small, T.M. Beer, G. Wilding, A. Martin,
and M. Hussain, Design and end points of clinical trials
for patients with progressive prostate cancer and castrate
levels of testosterone: recommendations of the prostate cancer
clinical trials working group. J Clin Oncol, 2008. 26(7):
p. 1148-59. |
| |
Publications – 2007 |
|
D'Amico, A.V., S. Halabi, C. Tempany, D.
Titelbaum, G.K. Philips, M. Loffredo, E. McMahon, B. Sanford,
N.J. Vogelzang, and E.J. Small, Tumor Volume Changes on 1.5
Tesla Endorectal Mri During Neoadjuvant Androgen Suppression
Therapy for Higher-Risk Prostate Cancer and Recurrence in
Men Treated Using Radiation Therapy Results of the Phase
Ii Calgb 9682 Study. Int J Radiat Oncol Biol Phys, 2007. |
|
Fong, L. and E.J. Small, Immunotherapy
for prostate cancer. Curr Oncol Rep, 2007. 9(3): p. 226-33. |
|
Garcia, J.A., J.E. Rosenberg, V. Weinberg,
J. Scott, M. Frohlich, J.W. Park, and E.J. Small, Evaluation
and significance of circulating epithelial cells in patients
with hormone-refractory prostate cancer. BJU Int, 2007. 99(3):
p. 519-24. |
|
Halabi, S., S.S. Ou, N.J. Vogelzang, and
E.J. Small, Inverse correlation between body mass index and
clinical outcomes in men with advanced castration-recurrent
prostate cancer. Cancer, 2007. 110(7): p. 1478-84. |
|
Halabi, S., N.J. Vogelzang, S.S. Ou, and
E.J. Small, The impact of prior radical prostatectomy in
men with metastatic castration recurrent prostate cancer:
a pooled analysis of 9 Cancer and Leukemia Group B Trials.
J Urol, 2007. 177(2): p. 531-4. |
|
Harzstark, A.L. and E.J. Small, Immunotherapy
for prostate cancer using antigen-loaded antigen-presenting
cells: APC8015 (Provenge). Expert Opin Biol Ther, 2007. 7(8):
p. 1275-80. |
|
Hsieh, A.C., E.J. Small, and C.J. Ryan,
Androgen-response elements in hormone-refractory prostate
cancer: implications for treatment development. Lancet Oncol,
2007. 8(10): p. 933-9. |
|
Lin, A.M., B.I. Rini, M.K. Derynck, V. Weinberg, M. Park, C.J. Ryan, J.E.
Rosenberg, G. Bubley, and E.J. Small, A phase I trial of docetaxel/estramustine/imatinib
in patients with hormone-refractory prostate cancer. Clin Genitourin Cancer,
2007. 5(5): p. 323-8. |
|
Lin, A.M., C.J. Ryan, and E.J. Small, Intermittent
chemotherapy for metastatic hormone refractory prostate cancer.
Crit Rev Oncol Hematol, 2007. 61(3): p. 243-54. |
|
Lin, A.M. and E.J. Small, Prostate cancer
update: 2006. Curr Opin Oncol, 2007. 19(3): p. 229-33. |
|
Rosenberg, J.E., V.K. Weinberg, W.K. Kelly,
D. Michaelson, M.H. Hussain, G. Wilding, M. Gross, D. Hutcheon,
and E.J. Small, Activity of second-line chemotherapy in docetaxel-refractory
hormone-refractory prostate cancer patients : randomized
phase 2 study of ixabepilone or mitoxantrone and prednisone.
Cancer, 2007. 110(3): p. 556-63. |
|
Ryan, C.J., S. Halabi, S.S. Ou, N.J. Vogelzang,
P. Kantoff, and E.J. Small, Adrenal androgen levels as predictors
of outcome in prostate cancer patients treated with ketoconazole
plus antiandrogen withdrawal: results from a cancer and leukemia
group B study. Clin Cancer Res, 2007. 13(7): p. 2030-7. |
|
Ryan, C.J., C.M. Haqq, J. Simko, D.F. Nonaka,
J.M. Chan, V. Weinberg, E.J. Small, and I.D. Goldfine, Expression
of insulin-like growth factor-1 receptor in local and metastatic
prostate cancer. Urol Oncol, 2007. 25(2): p. 134-40. |
|
Ryan, C.J., W.M. Stadler, B. Roth, D. Hutcheon,
S. Conry, T. Puchalski, C. Morris, and E.J. Small, Phase
I dose escalation and pharmacokinetic study of AZD2171, an
inhibitor of the vascular endothelial growth factor receptor
tyrosine kinase, in patients with hormone refractory prostate
cancer (HRPC). Invest New Drugs, 2007. |
|
Ryan, C.J., V. Weinberg, J. Rosenberg,
L. Fong, A. Lin, J. Kim, and E.J. Small, Phase II study of
ketoconazole plus granulocyte-macrophage colony-stimulating
factor for prostate cancer: effect of extent of disease on
outcome. J Urol, 2007. 178(6): p. 2372-6; discussion 2377. |
|
Small, E.J., J. Fontana, N. Tannir, R.S.
DiPaola, G. Wilding, M. Rubin, R.B. Iacona, and F.F. Kabbinavar,
A phase II trial of gefitinib in patients with non-metastatic
hormone-refractory prostate cancer. BJU Int, 2007. 100(4):
p. 765-9. |
|
Small, E.J., N. Sacks, J. Nemunaitis, W.J.
Urba, E. Dula, A.S. Centeno, W.G. Nelson, D. Ando, C. Howard,
F. Borellini, M. Nguyen, K. Hege, and J.W. Simons, Granulocyte
macrophage colony-stimulating factor--secreting allogeneic
cellular immunotherapy for hormone-refractory prostate cancer.
Clin Cancer Res, 2007. 13(13): p. 3883-91. |
|
Small, E.J., N.S. Tchekmedyian, B.I. Rini,
L. Fong, I. Lowy, and J.P. Allison, A pilot trial of CTLA-4
blockade with human anti-CTLA-4 in patients with hormone-refractory
prostate cancer. Clin Cancer Res, 2007. 13(6): p. 1810-5. |
| |
Publications – 2006 |
|
Fong, L. and E.J.
Small, Immunotherapy
for prostate cancer. Curr Urol Rep, 2006. 7(3): p. 239-46. |
|
Halabi, S., N.J. Vogelzang, S.S. Ou, W.K. Kelly, and E.J.
Small, Clinical Outcomes by Age in Men With Hormone Refractory
Prostate Cancer: A Pooled Analysis of 8 Cancer and Leukemia
Group B (CALGB) Studies. J Urol, 2006. 176(1): p. 81-6. |
|
Humphrey, P.A., S. Halabi, J. Picus, B.
Sanford, N.J. Vogelzang, E.J. Small, and
P.W. Kantoff, Prognostic significance of plasma scatter factor/hepatocyte
growth factor levels in patients with metastatic hormone-
refractory prostate cancer: results from cancer and leukemia
group B 150005/9480. Clin Genitourin Cancer, 2006. 4(4):
p. 269-74. |
|
Hussain, M., C.M. Tangen, C. Higano, P.F.
Schelhammer, J. Faulkner, E.D. Crawford, G. Wilding, A. Akdas,
E.J. Small, B. Donnelly, G. MacVicar, and D. Raghavan, Absolute
prostate-specific antigen value after androgen deprivation
is a strong independent predictor of survival in new metastatic
prostate cancer: data from Southwest Oncology Group Trial
9346 (INT-0162). J Clin Oncol, 2006. 24(24): p. 3984-90. |
|
Kornblith, A.B., J.M. Dowell, J.E.
Herndon, 2nd, B.J. Engelman, S. Bauer-Wu, E.J. Small, V.A.
Morrison, J. Atkins, H.J. Cohen, and J.C. Holland, Telephone
monitoring of distress in patients aged 65 years or older
with advanced stage cancer: a cancer and leukemia group B
study. Cancer, 2006. 107(11): p. 2706-14. |
|
Lin, A.M., R.M. Hershberg, and E.J. Small,
Immunotherapy for prostate cancer using prostatic acid phosphatase
loaded antigen presenting cells. Urol Oncol, 2006. 24(5):
p. 434-41. |
|
Lin, A.M., B.I. Rini, and E.J.
Small, Clinical trials
in patients with biochemically relapsed prostate cancer.
BJU Int, 2006. 97(5): p. 905-10. |
|
Lin, A.M., B.I. Rini, V. Weinberg,
K. Fong, C.J. Ryan, J.E. Rosenberg, L. Fong, and E.J. Small,
A phase II trial of imatinib mesylate in patients with biochemical
relapse of prostate cancer after definitive local therapy.
BJU Int, 2006. 98(4): p. 763-9. |
|
Lin, A.M., C.J. Ryan, and E.J. Small,
Intermittent chemotherapy for metastatic hormone refractory
prostate cancer. Crit Rev Oncol Hematol, 2006. |
|
Montie, J.E., N.A. Abrahams, R.R. Bahnson,
M.A. Eisenberger, R. El-Galley, H.W. Herr, G.R. Hudes, T.M.
Kuzel, P.H. Lange, A. Patterson, A. Pollack, J.P. Richie,
W.J. Sexton, W.U. Shipley, E.J. Small, D.L. Trump, P.J. Walther,
and T.G. Wilson, Bladder cancer. Clinical guidelines in oncology.
J Natl Compr Canc Netw, 2006. 4(10): p. 984-1014. |
|
Petrylak, D.P., D.P. Ankerst, C.S. Jiang, C.M. Tangen, M.H. Hussain, P.N. Lara, Jr., J.A. Jones, M.E. Taplin, P.A. Burch, M. Kohli, M.C. Benson, E.J.
Small, D. Raghavan, and E.D. Crawford, Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst, 2006. 98(8): p. 516-21. |
|
Rini, B.I., L. Fong, V. Weinberg, B. Kavanaugh, and E.J.
Small, Clinical and immunological characteristics of patients
with serologic progression of prostate cancer achieving long-term
disease control with granulocyte-macrophage colony-stimulating
factor. J Urol, 2006. 175(6): p. 2087-91. |
|
Rini, B.I., S. Halabi, R. Barrier, K.A.
Margolin, D. Avigan, T. Logan, W.M. Stadler, P.L. McCarthy,
C.A. Linker, and E.J. Small, Adoptive immunotherapy by allogeneic
stem cell transplantation for metastatic renal cell carcinoma:
a CALGB intergroup phase II study. Biol Blood Marrow Transplant,
2006. 12(7): p. 778-85. |
|
Rini, B.I., E. Jaeger, V. Weinberg, N.
Sein, K. Chew, K. Fong, J. Simko, E.J. Small, and F.M. Waldman,
Clinical response to therapy targeted at vascular endothelial
growth factor in metastatic renal cell carcinoma: impact
of patient characteristics and Von Hippel-Lindau gene status.
BJU Int, 2006. 98(4): p. 756-62. |
|
Rini, B.I., V. Weinberg, S. Dunlap, A. Elchinoff, N. Yu,
R. Bok, J. Simko, and E.J. Small, Maximal COX-2 immunostaining
and clinical response to celecoxib and interferon alpha therapy
in metastatic renal cell carcinoma. Cancer, 2006. 106(3):
p. 566-75. |
|
Rini, B.I., V. Weinberg, L. Fong, S. Conry, R.M. Hershberg,
and E.J. Small, Combination immunotherapy with prostatic
acid phosphatase pulsed antigen-presenting cells (provenge)
plus bevacizumab in patients with serologic progression of
prostate cancer after definitive local therapy. Cancer, 2006. |
|
Rosenberg, J.E., M.D. Galsky, N.C. Rohs, V.K. Weinberg,
W.K. Oh, W.K. Kelly, and E.J. Small, A retrospective evaluation
of second-line chemotherapy response in hormone-refractory
prostate carcinoma: second line taxane-based therapy after
first-line epothilone-B analog ixabepilone (BMS-247550) therapy.
Cancer, 2006. 106(1): p. 58-62. |
|
Ryan, C.J., E.P. Elkin, E.J. Small, J.
Duchane, and P. Carroll, Reduced incidence of bony metastasis
at initial prostate cancer diagnosis: data from CaPSURE.
Urol Oncol, 2006. 24(5): p. 396-402. |
|
Ryan, C.J., A.M. Lin, and E.J.
Small, Angiogenesis
inhibition plus chemotherapy for metastatic hormone refractory
prostate cancer: history and rationale. Urol Oncol, 2006.
24(3): p. 250-3. |
|
Ryan, C.J. and E.J.
Small, Prostate cancer update: 2005.
Curr Opin Oncol, 2006. 18(3): p. 284-8. |
|
Ryan, C.J. and E.J. Small, Androgen deprivation
therapy in locally advanced and metastatic prostate cancer.
Minerva Urol Nefrol, 2006. 58(3): p. 119-26. |
|
Ryan, C.J. and E.J. Small, High risk biochemical
relapse and the timing of androgen deprivation therapy. J
Urol, 2006. 176(6 Pt 2): p. S61-5. |
|
Small, E.J., M.A. Carducci, J.M. Burke, R. Rodriguez,
L. Fong, L. van Ummersen, D.C. Yu, J. Aimi, D. Ando, P. Working,
D. Kirn, and G. Wilding, A Phase I Trial of Intravenous CG7870,
a Replication-Selective, Prostate-Specific Antigen-Targeted
Oncolytic Adenovirus, for the Treatment of Hormone-Refractory,
Metastatic Prostate Cancer. Mol Ther, 2006. |
|
Small, E.J., S. Halabi, P. Kantoff, A. D'Amico, W. Stadler, W.K. Kelley, J. Mohler, D. Bajorin, and N.J. Vogelzang, Activities and accomplishments of the cancer and leukemia group B genitourinary committee. Clin Cancer Res, 2006. 12(11 Pt 2): p. 3596s-600s. |
|
Small, E.J. and C.J. Ryan, The case for
secondary hormonal therapies in the chemotherapy age. J Urol,
2006. 176(6 Pt 2): p. S66-71. |
|
Small, E.J., P.F. Schellhammer, C.S. Higano,
C.H. Redfern, J.J. Nemunaitis, F.H. Valone, S.S. Verjee,
L.A. Jones, and R.M. Hershberg, Placebo-controlled phase
III trial of immunologic therapy with sipuleucel-T (APC8015)
in patients with metastatic, asymptomatic hormone refractory
prostate cancer. J Clin Oncol, 2006. 24(19): p. 3089-94. |
|
So-Rosillo, R. and E.J. Small, Sipuleucel-T
(APC8015) for prostate cancer. Expert Rev Anticancer Ther,
2006. 6(9): p. 1163-7. |
|
Stadler, W.M., S. Halabi, B. Rini, M.S.
Ernstoff, E. Davila, J. Picus, R. Barrier, and E.J. Small,
A phase II study of gemcitabine and capecitabine in metastatic
renal cancer: a report of Cancer and Leukemia Group B protocol
90008. Cancer, 2006. 107(6): p. 1273-9. |
|
Wilding, G., P. Soulie, D. Trump, A. Das-Gupta, and E.
Small, Results from a pilot Phase I trial of gefitinib combined
with docetaxel and estramustine in patients with hormone-refractory
prostate cancer. Cancer, 2006. 106(9): p. 1917-24. |
| |
return
to top
|
|
|
|
|
|
